N

Nykode Therapeutics ASA
OSE:NYKD

Watchlist Manager
Nykode Therapeutics ASA
OSE:NYKD
Watchlist
Price: 2.812 NOK 4.38% Market Closed
Market Cap: 918.2m NOK
Have any thoughts about
Nykode Therapeutics ASA?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

0.9
Current
-9.4
Median
4.2
Industry
Higher than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
0.9
=
Enterprise Value
-568.5m NOK
/
EBITDA
-56.6m USD
All Countries
Close
Market Cap EV/EBITDA
NO
Nykode Therapeutics ASA
OSE:NYKD
918.2m NOK 0.9
FR
Pharnext SCA
OTC:PNEXF
6T USD -218 147.8
US
Abbvie Inc
NYSE:ABBV
325.5B USD 15.8
US
Amgen Inc
NASDAQ:AMGN
150.4B USD 16.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.9B USD 25.1
US
Gilead Sciences Inc
NASDAQ:GILD
115.7B USD 10.2
US
Epizyme Inc
F:EPE
94.1B EUR -517.9
AU
CSL Ltd
ASX:CSL
135.7B AUD 20.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
83.7B USD 16.4
US
Seagen Inc
F:SGT
39.3B EUR -59.2
NL
argenx SE
XBRU:ARGX
34.6B EUR -105.5
EBITDA Growth
NO
N
Nykode Therapeutics ASA
OSE:NYKD
Average EV/EBITDA: 15.1
0.9
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -218 147.8 N/A
US
Abbvie Inc
NYSE:ABBV
15.8
29%
US
Amgen Inc
NASDAQ:AMGN
16.8
62%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.1
43%
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
16%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -517.9 N/A
AU
CSL Ltd
ASX:CSL
20.5
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.4
35%
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.2 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -105.5 N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
9.7
2-Years Forward
EV/EBITDA
10.8
3-Years Forward
EV/EBITDA
7

See Also

Discover More